Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 10/20 | 0.37 |
| ▸ | AKT2 | P31751 | 9/20 | 0.37 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17822929 | 0.99 | AKT1 (0.37) | AKT1AKT2AKT3BRD4CREBBP | |
| SCHEMBL17823035 | 0.85 | AKT1 (0.39) | AKT1AKT2AKT3MAPK14KDM4E | |
| SCHEMBL17823113 | 0.85 | CREBBP (0.39) | AKT1AKT2AKT3BRD4CREBBP | |
| Hydrochloric Acid SCHEMBL19715280 | 0.85 | AKT1 (0.38) | AKT1AKT2AKT3MAPK14KDM4E | |
| Hydrochloric Acid SCHEMBL19715273 | 0.84 | CREBBP (0.38) | AKT1AKT2AKT3BRD4CREBBP | |
| SCHEMBL17823062 | 0.84 | MAPK1 (0.44) | AKT1AKT2AKT3MAPK14 | |
| Hydrochloric Acid SCHEMBL17823102 | 0.83 | MAPK1 (0.44) | AKT1AKT2AKT3MAPK14 | |
| SCHEMBL17822982 | 0.83 | AKT1 (0.38) | AKT1AKT2AKT3MAPK14CTSS | |
| SCHEMBL21374212 | 0.83 | KDM4E (0.42) | AKT1AKT2AKT3MAPK14KDM4E | |
| Hydrochloric Acid SCHEMBL17823114 | 0.82 | AKT1 (0.37) | AKT1AKT2AKT3MAPK14CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207474-B | Substituted heterocycles as bromodomain inhibitors | 恒翼生物医药科技(上海)有限公司 | 2021-05-07 | — | — | CN | claimed |
| EP-3230277-B1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2019-09-18 | — | — | EP | claimed |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-05-21 | — | — | US | claimed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | claimed |
| CN-107207474-B | Substituted heterocycles as bromodomain inhibitors | 恒翼生物医药科技(上海)有限公司 | 2021-05-07 | — | — | CN | disclosed |
| EP-3230277-B1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2019-09-18 | — | — | EP | disclosed |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-05-21 | — | — | US | disclosed |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-05-21 | — | — | US | disclosed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| EP-3230277-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | Zenith Epigenetics Ltd. (CA) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092375-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | AKT1 1351/4885AKT2 2118/4885AKT3 1735/4885 |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | BRD4, BRD3, BRD1 | AKT1 1351/4885AKT2 2118/4885AKT3 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.